Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

Glioblastoma (GBM) heterogeneity, aggressiveness and infiltrative growth drastically limit success of current standard of care drugs and efficacy of various new therapeutic approaches. There is a need for new therapies and models reflecting the complex biology of these tumors to analyze the molecula...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Joshua Alcaniz, Lars Winkler, Mathias Dahlmann, Michael Becker, Andrea Orthmann, Johannes Haybaeck, Stefanie Krassnig, Christina Skofler, Tobias Kratzsch, Susanne A. Kuhn, Andreas Jödicke, Michael Linnebacher, Iduna Fichtner, Wolfgang Walther, Jens Hoffmann
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2023-04-01
سلاسل:	Frontiers in Oncology
الموضوعات:	glioblastoma glioma patient-derived xenograft (PDX) preclinical oncology drug efficacy targeted therapy
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1129627/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!